Atherys

Atherys is a French biotechnology company developing a novel class of immunotherapies designed to treat chronic inflammatory diseases, with a primary focus on atherosclerosis. The company's proprietary platform focuses on the induction of antigen-specific regulatory T cells (Tregs) to restore immune homeostasis and prevent the progression of arterial plaques. By targeting the underlying autoimmune-like mechanisms of cardiovascular disease, Atherys aims to provide a transformative alternative to current lipid-lowering therapies. Their lead program is a therapeutic vaccine currently in pre-clinical development, supported by foundational research from INSERM and the University of Cambridge.